Goliath Intercepts 9.40 g/t AuEq Over 7.00 Meters in Bonanza Shear Within The Golden Gate Feeder Zone Confirming An Extensive Stacked System Containing Multiple Bonanza-Grade Veins Over 1.8 Km2 on Golddigger, Remains Wide Open - Golden Triangle, British Columbia
08 nov. 2023 08h11 HE
|
Goliath Resources Limited
Drill Highlights: GD-23-170 collared from Pad 16 intercepted numerous occurrences of Visible Gold, as well as strong sulphides mineralization in quartz-stockwork and veins corresponding with the...
Goliath Drills 66.34 Meters* of Sulphide-Rich Quartz Breccia Including Visible Gold Over 20.05 Meters* at Surebet Golden Gate Feeder Zone, Golden Triangle, B.C.
31 juil. 2023 07h08 HE
|
Goliath Resources Limited
Drill Hole GD-23-157 Highlights: Visible Gold has been identified over a 20.05 meter* interval (65.78 feet*) between 119.07 and 139.12 meters inclusive of twelve (12) separate Visible Gold...
Oncotelic Presenting Data for OT101 Against Diffuse Intrinsic Pontine Glioma (DIPG) at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
14 sept. 2022 08h15 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
Incysus Therapeutics to Present at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
21 nov. 2019 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Gamma-Delta (γδ) T Cell Therapy Combined With Checkpoint Inhibition Shows Potential Synergies in Vitro for Treatment of Glioblastoma
15 nov. 2018 07h00 HE
|
Incysus Therapeutics, Inc.
Promising data from gamma-delta (γδ) T cell therapy in combination with checkpoint inhibitors to be presented at 2018 Society for Neuro-Oncology annual meeting NEW YORK, Nov. 15, 2018 (GLOBE...
VBI Vaccines to Present Initial Data for VBI-1901 in Recurrent Glioblastoma (GBM) Patients at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)
24 oct. 2018 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...